TEVA
What one share of Teva Pharmaceutical Industries Limited holds
Pharmaceutical Preparations
We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients’ needs, now and in the future.
Teva Pharmaceutical Industries Limited’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.88 |
|---|---|
| Profit | $0.61 |
| Capex (buildings and equipment) | $0.47 |
| Free cash flow | $1.16 |
| Cash and investments | $3.14 |
| Debt | $14.29 |
| Book value | $6.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $22.79 | $0.07 | $0.94 | $3.11 | $1.36 | $29.68 |
| 2017 | $21.51 | −$16.26 | $0.86 | $1.33 | $0.85 | $17.09 |
| 2018 | $17.90 | −$2.35 | $0.64 | $1.76 | $0.00 | $13.50 |
| 2019 | $15.48 | −$0.92 | $0.48 | $0.20 | $0.00 | $12.79 |
| 2020 | $15.21 | −$3.64 | $0.53 | $0.58 | — | $9.14 |
| 2021 | $14.34 | $0.38 | $0.51 | $0.21 | — | $9.32 |
| 2022 | $13.45 | −$2.20 | $0.49 | $0.94 | — | $7.02 |
| 2023 | $14.16 | −$0.50 | $0.47 | $0.75 | — | $6.70 |
| 2024 | $14.63 | −$1.45 | $0.44 | $0.66 | — | $4.74 |
| 2025 | $14.84 | $1.21 | $0.43 | $0.99 | — | $6.88 |